Healthcare
Live Price
Offline$18.18
+1.68% today
1Y Change
-52.60%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zai Lab Limited (ZLAB) is a Healthcare stock with a market cap of $2.39B and listed on NASDAQ. The stock last traded around $18.18 and down 52.6% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +15.3%, EPS growth of +38.5%, a dividend yield of 0.0%. What stands out right now is revenue +15.3%, EPS +38.5%, free cash flow +42.5% with operating margin -49.9% and ROIC -23.3%. Valuation sits in the middle of the pack at price/sales 5.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ZLAB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZLAB
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZLAB Max Drawdown
-59.76%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZLAB and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$144.3M
-32.9% YoY
FY Net Income
-$704.5M
-58.9% YoY
Free Cash Flow
-$568.2M
-44.7% YoY
Revenue Growth
+15.3%
EPS Growth
+38.5%
Gross Margin
58.5%
Net Margin
-38.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 460M | 399M | 267M | 215M | 144M |
| Gross Profit | 270M | 251M | 171M | 141M | 92M |
| Operating Income | -229M | -282M | -367M | -404M | -700M |
| EBITDA | -158M | -235M | -365M | -435M | -689M |
| Net Income | -176M | -257M | -335M | -443M | -704M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 680M | 450M | 790M | 1.0B | 964M |
| Total Assets | 1.2B | 1.2B | 1.0B | 1.2B | 1.6B |
| Total Liabilities | 457M | 345M | 240M | 175M | 230M |
| Shareholder Equity | 716M | 841M | 796M | 1.0B | 1.4B |
| Total Debt | 224M | 153M | 15M | 20M | 16M |
| Net Debt | -455M | -296M | -775M | -988M | -949M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
549M
-49.4% YoY
Capital Expenditures
19M
+24.2% YoY
Free Cash Flow
568M
-44.7% YoY
Key ratios
Gross Margin
58.5%
Operating Margin
-49.9%
Net Margin
-38.1%
ROE
-22.8%
Debt / Equity
0.33x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.